- Reviews (0)
|Applications||IHC IP WB|
|Antigen/Gene or Protein Targets||Fbxo7|
|Reactivity||Human and Mouse|
Recessive mutations in FBXO7/PARK15 cause an atypical EOPD. In certain cancers, the protein is highly expressed.
These cell lines all express Fbxo7: U2OS, SHSY5Y, HEK293, Jurkat, SKOV3, HeLa, Ba-F3, Nalm6, C33A, MEL, HSPCs, MEFs.
|Immunogen||aa 499-522 of human Fbxo7 synthetic peptide coupled to KLH|
|Molecular Weight (kDa)||~59/~70|
Staining Pattern: Nuclear and cytoplasmic, depending on stage of the cell cycle. May be aberrantly localised in pathological conditions.
This antibody is not available for licence, please refer to supplier information to find a source of the antibody.
|Positive Control||Any cultured cell line grown in FBS|
|Research Area||Cell Cycle, Epigenetics & Nuclear Signalling|
Have you used this reagent? Share your experience by submitting a review and help your fellow scientists.Review this reagent